We also showed that treatment with a neutralizing anti-TGF-β mAb ameliorated HFD-induced AHR, lung fibrosis, and goblet cell hyperplasia in the OVA-induced asthma model, which reflected the possible role of anti-TGF-β treatment in asthmatic patients with obesity or patients with severe asthma. The gene discussed is TGFB1; the disease is fibrosis.